Thomas Marron, MD, PhD
img_Thomas Marron
PROFESSOR | Immunology & Immunotherapy
PROFESSOR | Medicine, Hematology and Medical Oncology
Are you a patient?
Specialties
Internal Medicine, Cancer (Oncology)

MD, Icahn School of Medicine at Mount Sinai

Residency, Internal Medicine, Mount Sinai Hospital and Medical Center

Fellowship, Medical Oncology, Mount Sinai Hospital and Medical Center

Certifications

American Board of Internal Medicine
Publications

Selected Publications

Consolidation ALK Tyrosine Kinase Inhibitors Versus Durvalumab or Observation After Chemoradiation in Unresectable Stage III ALK-Positive NSCLC. Amin H. Nassar, Ritujith Jayakrishnan, Jamie Feng, Frances Shepherd, Elio Adib, Justin M. Cheung, Jessica J. Lin, Yufei Liu, Steven H. Lin, Kaushal Parikh, Arthi Sridhar, Purnima Shakya, Thomas J. Dilling, David Kaldas, Jhanelle E. Gray, Anastasiya Lobachov, Jair Bar, Heike Luders, Christian Grohe, Shruti Gupta, Ticiana Leal, Bailey Fitzgerald, Fionnuala Crowley, Yu Fujiwara, Thomas U. Marron, Molly Wilgucki, Joshua Reuss, Luxi Chen, Kamya Sankar, Jacqueline V. Aredo, Joel W. Neal, Heather A. Wakelee, Rohit Thummalapalli, Helena Yu, Ryan Whitaker, Ana Velazquez, Meera Ragavan, Alessio Cortellini, David J. Kwiatkowski, Abdul Rafeh Naqash, Sarah B. Goldberg, So Yeon Kim. Journal of Thoracic Oncology

Prediction of checkpoint inhibitor immunotherapy efficacy for cancer using routine blood tests and clinical data. Seong Keun Yoo, Conall W. Fitzgerald, Byuri Angela Cho, Bailey G. Fitzgerald, Catherine Han, Elizabeth S. Koh, Abhinav Pandey, Hannah Sfreddo, Fionnuala Crowley, Michelle Rudshteyn Korostin, Neha Debnath, Yan Leyfman, Cristina Valero, Mark Lee, Joris L. Vos, Andrew Sangho Lee, Karena Zhao, Stanley Lam, Ezekiel Olumuyide, Fengshen Kuo, Eric A. Wilson, Pauline Hamon, Clotilde Hennequin, Miriam Saffern, Lynda Vuong, A. Ari Hakimi, Brian Brown, Miriam Merad, Sacha Gnjatic, Nina Bhardwaj, Matthew D. Galsky, Eric E. Schadt, Robert M. Samstein, Thomas U. Marron, Mithat Gönen, Luc G.T. Morris, Diego Chowell. Nature Medicine

Lung cancer research and treatment: global perspectives and strategic calls to action. M. L. Meyer, S. Peters, T. S. Mok, S. Lam, P. C. Yang, C. Aggarwal, J. Brahmer, R. Dziadziuszko, E. Felip, A. Ferris, P. M. Forde, J. Gray, L. Gros, B. Halmos, R. Herbst, P. A. Jänne, B. E. Johnson, K. Kelly, N. B. Leighl, S. Liu, I. Lowy, T. U. Marron, L. Paz-Ares, N. Rizvi, C. M. Rudin, E. Shum, R. Stahel, N. Trunova, P. A. Bunn, F. R. Hirsch. Annals of Oncology

View All Publications

Cancer Immunotherapy: In search of the other "c" word for our cancer patients (cure)

Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device, biotechnology companies, and other outside entities to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their outside financial relationships.

Below are financial relationships with industry reported by Dr. Marron during 2024 and/or 2025. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.

Consulting or Other Professional Services Examples include, but are not limited to, committee participation, data safety monitoring board (DSMB) membership

  • Storm
  • Ono Pharmaceuticals
  • Geneos Therapeutics, Inc,
  • Replimune
  • EMD Serono, Inc
  • Arrowhead Research Corporation
  • NTx Natures Toolbox

Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.